NDAINTRAVENOUSSOLUTION
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
4/8 — Partial
ASCOR (ascorbic acid) by Fresenius Kabi is 12. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASCOR (ascorbic acid) is an intravenous vitamin C solution approved by the FDA in 2017 for the treatment of scurvy, a disorder caused by severe vitamin C deficiency. The drug restores body pools of ascorbic acid through a mechanism that remains incompletely understood. It is administered as an intravenous infusion and is distributed widely throughout the body, with high concentrations in the liver, leukocytes, platelets, and glandular tissues.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable commercial performance but limited growth upside for brand team expansion.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The exact mechanism of action of ascorbic acid for the treatment of symptoms and signs of scurvy (a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to…
Worked on ASCOR at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.